1. Home
  2. ISOU vs DCTH Comparison

ISOU vs DCTH Comparison

Compare ISOU & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ISOU

IsoEnergy Ltd.

HOLD

Current Price

$9.07

Market Cap

680.3M

Sector

N/A

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$15.75

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISOU
DCTH
Founded
2016
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.3M
578.4M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
ISOU
DCTH
Price
$9.07
$15.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $22.00
AVG Volume (30 Days)
135.4K
★ 289.8K
Earning Date
05-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
★ N/A
$392.25
Revenue Growth
N/A
N/A
52 Week Low
$7.19
$8.12
52 Week High
$13.58
$17.42

Technical Indicators

Market Signals
Indicator
ISOU
DCTH
Relative Strength Index (RSI) 35.91 45.99
Support Level $7.80 $15.68
Resistance Level $12.19 $16.51
Average True Range (ATR) 0.54 0.45
MACD -0.18 -0.13
Stochastic Oscillator 3.38 27.43

Price Performance

Historical Comparison
ISOU
DCTH

About ISOU IsoEnergy Ltd.

IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Geiger, Thorburn Lake, Full Moon, Edge, Collins Bay Extension, North Thorburn, 2Z Lake, and Madison. It operates in Canada, the United States, and Australia.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: